Holen Sie sich die Stockscreener-App
42.07
2.30%
-0.99
Handel nachbörslich:
42.07
Schlusskurs vom Vortag:
$43.06
Offen:
$42.5
24-Stunden-Volumen:
896.16K
Relative Volume:
0.68
Marktkapitalisierung:
$8.75B
Einnahmen:
$1.97B
Nettoeinkommen (Verlust:
$92.93M
KGV:
103.47
EPS:
0.4066
Netto-Cashflow:
$459.60M
1W Leistung:
+3.34%
1M Leistung:
+6.05%
6M Leistung:
-1.56%
1J Leistung:
-0.43%
1-Tages-Spanne:
$41.82
$42.59
1-Wochen-Bereich:
$40.31
$43.13
52-Wochen-Spanne:
$37.74
$49.30
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie QGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
42.07 | 8.75B | 1.97B | 92.93M | 459.60M | 0.4066 |
|
TMO
Thermo Fisher Scientific Inc
|
424.24 | 159.25B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.14 | 132.37B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
437.44 | 32.95B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
106.28 | 28.58B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
150.28 | 24.90B | 15.41B | 1.37B | 2.11B | 7.50 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-04 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
Next-Generation Sequencing (NGS) Data Analysis Market to Hit USD 4.21 Billion by 2032, Driven by Rising Genomic Research and Precision Medicine Initiatives – SNS Insider - GlobeNewswire Inc.
QIAGEN NV : UBS reiterates its Neutral rating - marketscreener.com
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025 | QGEN Stock News - GuruFocus
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025 - Business Wire
Is There An Opportunity With Qiagen N.V.'s (NYSE:QGEN) 33% Undervaluation? - Yahoo Finance
QIAGEN N.V. Prepares to Release 2024 Financial Reports - TipRanks
PTA-AFR: QIAGEN N.V.: Pre-announcement of a financial report according to articles 114117 WpHG - TradingView
Baird Increases Price Target for Qiagen (QGEN) Ahead of Q1 Results | QGEN Stock News - GuruFocus
What Qiagen N.V.'s (NYSE:QGEN) P/S Is Not Telling You - simplywall.st
Fivespan Said to Build Stake in Life Sciences Group Qiagen - MSN
Qiagen’s Voting Rights Announcement Involves Major Financial Entities - TipRanks
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Fivespan Is Said to Build Stake in Life Sciences Group Qiagen - MSN
Qiagen's Future Under The Microscope After Stake Purchase - Finimize
Fivespan Partners Positions Itself in Qiagen (QGEN) Amid Activis - GuruFocus
Qiagen Holds Talks With Fivespan as Activist Investor Builds Stake - marketscreener.com
Activist investor Fivespan takes stake in QiagenBloomberg (QGEN:NYSE) - Seeking Alpha
QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation - 01net
QIAGEN's Lab Revolution: New Automation Systems Promise 3x Faster Sample Processing - Stock Titan
Qiagen (QGEN) Target Price Reduced Amid Negative Market Sentimen - GuruFocus
BofA Securities Cuts Price Target on Qiagen to $50 From $55, Maintains Buy Rating - MarketScreener
QIAGEN Announces Voting Rights Notification by AFM - TipRanks
Qiagen gains after guidance raise - MSN
Qiagen Announces Change in Total Voting Rights - TipRanks
PTA-NVR: QIAGEN N.V.: Total Voting Rights Announcement according to Article 41 of the WpHG - TradingView
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast - sharewise.com
QIAGEN Earnings Alert: Key Q1 2025 Results Coming May 7What to Watch - Stock Titan
Qiagen Q1 Preliminary Adjusted Earnings Beat Guidance; 2025 Outlook Lifted -- Shares Rise - MarketScreener
Qiagen stock gains after guidance raise (QGEN:NYSE) - Seeking Alpha
Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance - Benzinga
Qiagen: Q1 beat; profitability guidance upgraded - MarketScreener
QIAGEN NV : Deutsche Bank maintains a Buy rating - marketscreener.com
QIAGEN NV : UBS gives a Neutral rating - MarketScreener
Qiagen the only DAX stock to risehigher profit forecast helps - MarketScreener
QIAGEN NV : Jefferies gives a Buy rating - marketscreener.com
QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook - Yahoo Finance
EQS-Adhoc: QIAGEN N.V.: QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook - sharewise.com
QIAGEN Crushes Q1 Targets: Key Products Surge, EPS Guidance Raised to $2.35 - Stock Titan
Qiagen Says Q1 Adjusted EPS $0.55 - MarketScreener
QIAGEN Smashes Q1 Targets: 7% Growth Powers Confident 2025 Outlook Boost - Stock Titan
Redburn Atlantic Downgrades Qiagen N.V. (BIT:1QGEN) - Nasdaq
Redburn Atlantic Downgrades Qiagen N.V. (LSE:0RLT) - Nasdaq
Qiagen Announces Voting Rights Update with Bank of America - TipRanks
Redburn cuts QIAGEN stock rating, lowers price target to EUR41 - Investing.com
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):